Is 'Low T' a Real Disease or Marketing Ploy?

The prevalence of 'low T' has surged, with UK prescriptions for testosterone increasing by 135% between 2021 and 2024. This rise is partly driven by direct-to-consumer men's health companies, which target men through social media and offer TRT. These companies are accused by some endocrinologists of overdiagnosing testosterone deficiency, leading to unnecessary anxiety.

Advocates for TRT argue that the NHS underdiagnoses the condition, denying men vital care. The medical definition of hypogonadism requires low testosterone levels coupled with specific symptoms like erectile dysfunction, low libido, or depression.

However, concerns persist about the marketing of TRT. Critics suggest that companies may be widening the definition of low testosterone to create a larger market, especially with private equity investment in TRT clinics. The line between therapeutic TRT and non-medical use, such as 'T-maxxing' for performance enhancement, is also a significant point of debate.

Evidence on the benefits of TRT for otherwise healthy men remains mixed. While studies link diagnosed hypogonadism to higher mortality risks, concerns exist about potential side effects and the risks associated with testosterone abuse, including increased heart disease risk and psychological impacts.